Explorez tous les épisodes du podcast Peptide Show
| Titre | Date | Durée | |
|---|---|---|---|
| Conrad Campbell: How do you build a peptide factory in China? | 29 sept. 2026 | 00:23:18 | |
How do peptides get from a factory in China to a price list in your DMs? Conrad Campbell is a Scotsman building a peptide factory in China. After ten years in the military, he built businesses selling furniture, opening gyms, and trading online. Then he entered the peptide business, sourcing products from Chinese manufacturers for clients in the West. Understanding the supply chain gave him an idea: build a factory of his own. A fairly committed approach to checking your supplier. Along the way, he learned how the gray market operates. He describes products leaving factories through the back door, passing through warehouses and middlemen, and being sold over WhatsApp. Plenty of people taking a cut. Rather less clarity about who takes responsibility. Conrad says he wants to make that trade safer and more transparent. His ambitions sit within a much bigger story: empty biotech parks built for future demand, manufacturers planning decades ahead, and a Chinese industry he believes the US will struggle to catch. He explains: ■ Building a peptide factory in China Chapters
Watch the full episode on YouTube Further reading Research: A study of Chinese suppliers advertising GLP-1 medicines online, including their marketing, shipping, and quality claims: Made in China: The international supply of illicit semaglutide and weight-loss medicines online. JAMA Network Open: A 2024 study testing semaglutide purchased online without a prescription for drug content, purity, and contamination: Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases. FDA: Manufacturing standards, quality controls, and why testing a finished product is only part of the process: Facts About Current Good Manufacturing Practice. FDA: Current concerns around unapproved GLP-1 drugs, including products sold directly to consumers under research-use labels: FDA: Concerns with unapproved GLP-1 drugs. Follow Conrad Campbell Instagram: @conrad Follow Richard Skaife LinkedIn: linkedin.com/in/richardskaife/ Follow Peptide Show Website: Peptide.Show Peptide Show explores the science, medicine, business, and people shaping the rapidly evolving world of peptides. Presented by Longr: longr.io Follow Peptide Show for new episodes every Tuesday. This podcast is for informational and educational purposes only and does not constitute medical advice. Some compounds discussed in this episode are investigational, unapproved for the uses discussed, or subject to changing regulatory requirements. | |||
| Ksenia Petrushkina: Why are teenagers injecting peptides? | 22 sept. 2026 | 00:27:46 | |
What happens when people start experimenting with peptides before seeing a clinician? Ksenia Petrushkina sees the impact of peptides up close. As Director of Regenerative Medicine at Ideal Medical in Miami, she works with patients using peptides, longevity therapeutics, and regenerative medicine, including people who arrive after already starting protocols they found online. Before clinical medicine, Ksenia worked in cancer research. It taught her a lesson that still shapes how she thinks about peptides today: what looks extraordinary in a laboratory can fall apart completely in the real world. Now she sees the problem from the other direction. Patients arrive with gray-market vials, protocols copied from influencers, and stacks containing multiple experimental compounds. Some are teenagers. Ksenia is not anti-peptide. But she believes enthusiasm is moving faster than the evidence, and that separating promising biology from what is actually proven in humans will determine the future of peptide medicine. She explains: ■ Why teenagers are buying and injecting peptides they find online Chapters
Watch the full episode on YouTube Further reading FDA: July 2026 Pharmacy Compounding Advisory Committee review covering BPC-157, TB-500, MOTS-c, and other peptide-related bulk substances: FDA PCAC July 2026 meeting FDA: Current concerns around unapproved GLP-1 drugs, including retatrutide: FDA: Concerns with unapproved GLP-1 drugs PubMed: Review of the safety, evidence, and regulatory status of approved and unapproved peptide therapies: Safety and Efficacy of Approved and Unapproved Peptide Therapies PubMed: 2025 pilot study of intravenous BPC-157 in two human participants, discussed in the episode: Safety of Intravenous Infusion of BPC157 in Humans
Instagram: @dr.kseniamiami
LinkedIn: linkedin.com/in/richardskaife/
Website: Peptide.Show Peptide Show explores the science, medicine, business, and people shaping the rapidly evolving world of peptides. Presented by Longr: longr.io Follow Peptide Show for new episodes every Tuesday. This podcast is for informational and educational purposes only and does not constitute medical advice. Some compounds discussed in this episode are investigational, unapproved for the uses discussed, or subject to changing regulatory requirements. | |||
| Dylan Gemelli: Can you trust the peptides you’re buying? | 15 sept. 2026 | 00:30:43 | |
What happens when the people profiting from peptides have different motives from the people relying on them? For the past 15 years, the fitness and biohacking educator and host of The Dylan Gemelli Podcast has watched peptides move from bodybuilding forums and research chemical sites into the mainstream. Then the market changed around him. GLP-1s propelled peptides into public consciousness. BPC-157 became one of the compounds most closely associated with the category. And an underground market expanded alongside them, where suppliers, testing and certificates of analysis can create an appearance of certainty that may not always be justified. Gemelli believes peptides have far more potential than the handful of compounds dominating the conversation. But he is equally concerned by what happens when consumers buy from unregulated suppliers, assume a COA proves quality, or trust that what is on the label is what is actually in the vial. He explains: ■ How peptides went from obscure research chemicals to the mainstream Chapters
Watch the full episode on YouTube Further reading FDA: Concerns around unapproved GLP-1 drugs, foreign APIs, illegal online sales and products marketed as being for research purposes: FDA: Concerns with unapproved GLP-1 drugs FDA: July 2026 Pharmacy Compounding Advisory Committee meeting covering BPC-157, KPV, TB-500, MOTS-c and other peptide-related bulk substances: FDA PCAC July 2026 meeting Follow Dylan Gemelli Instagram: Instagram.com/dylangemelli Follow Richard Skaife LinkedIn: https://www.linkedin.com/in/richardskaife/ Peptide Show Website: Peptide.Show The Peptide Show explores the science, medicine, business and people shaping the rapidly evolving world of peptides. Presented by Longr: longr.io Follow The Peptide Show for new episodes every Tuesday. This podcast is for informational and educational purposes only and does not constitute medical advice. Some compounds discussed in this episode are investigational, unapproved for the uses discussed, or subject to changing regulatory requirements. | |||
| Dr Terry Dubrow: Are peptides about to change everything? | 08 sept. 2026 | 00:23:41 | |
What happens when millions of people want drugs their doctors can’t prescribe? Very few doctors become household names. Dr Terry Dubrow is one of them. For more than two decades, the board-certified plastic surgeon and star of Botched has sat at the intersection of medicine and popular culture, becoming one of the most recognizable doctors in America. Then peptides changed the direction of his career. Decades into an already established surgical career, Dr Dubrow went back to study, became board-certified in obesity medicine, and developed what he describes as an obsession with peptides, longevity and what could become the next frontier of medicine. He believes peptides could transform healthcare. But as unapproved compounds move online, patients bypass doctors and regulation struggles to keep pace, he is warning that the same revolution could also produce a serious medical backlash. He explains: ■ Why GLP-1s changed the direction of his career and pulled him into peptide medicine Chapters
Watch the full episode on YouTube Further reading FDA: July 2026 Pharmacy Compounding Advisory Committee meeting covering BPC-157, TB-500, MOTS-c and other peptide-related bulk substances: FDA PCAC July 2026 meeting ClinicalTrials.gov: Phase 3 TRIUMPH-1 study of retatrutide in obesity and overweight: Retatrutide TRIUMPH-1 trial Follow Dr Terry Dubrow Instagram: Instagram.com/drdubrow Follow Richard Skaife LinkedIn: https://www.linkedin.com/in/richardskaife/ The Peptide Show Website: Peptide.Show The Peptide Show explores the science, medicine, business and people shaping the rapidly evolving world of peptides. Presented by Longr: longr.io Follow The Peptide Show for new episodes every Tuesday. This podcast is for informational and educational purposes only and does not constitute medical advice. Some compounds discussed in this episode are investigational, unapproved for the uses discussed, or subject to changing regulatory requirements. | |||
| Introducing The Peptide Show | 07 sept. 2026 | 00:00:37 | |
The Peptide Show explores the science, medicine and business of peptides, with the people shaping what comes next. Hosted by Richard Skaife, new episodes arrive every Tuesday. Episode 1 features Dr Terry Dubrow on peptides, GLP-1s, longevity, regulation and why he believes this field could change medicine. Presented by Longr. Follow The Peptide Show so you don't miss the first episode. | |||